Melanoma Therapeutics Market Report 2026

The melanoma therapeutics market size has grown rapidly in recent years. It will grow from $4.47 billion in 2025 to $4.94 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to rising melanoma incidence, development of monoclonal antibodies, increased awareness of skin cancer, advancements in radiation therapy, adoption of dermatoscopy,.

The melanoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $7.49 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to growth in precision medicine, expansion of immunotherapy treatments, innovations in small molecule inhibitors, increasing healthcare expenditure, rising adoption of AI in diagnostics. Major trends in the forecast period include personalized melanoma therapy development, immunotherapy adoption growth, targeted therapy innovation, advanced diagnostic techniques integration, combination treatment strategies.

The increasing incidence of melanoma is expected to drive the growth of the melanoma therapeutics market in the coming years. Melanoma is a form of skin cancer that originates in melanocytes, the cells responsible for skin pigmentation. Melanoma therapeutics include a range of treatments and drugs used to manage and treat patients with melanoma by targeting cancer cells and reducing disease progression. As the incidence of melanoma continues to rise, the demand for effective therapeutic options increases, thereby boosting sales in the melanoma therapeutics market. For instance, in August 2024, according to a report published by the Australian Institute of Health and Welfare, Australia is projected to record approximately 209,000 new cancer diagnoses by 2034, a substantial increase from the estimated 169,000 cases expected in 2024, reflecting population growth and rising cancer rates. In addition, cancer is expected to account for nearly three out of every ten deaths in Australia in 2024. Therefore, the rising incidence of melanoma is contributing to the growth of the melanoma therapeutics market.

Companies operating in the melanoma therapeutics market are concentrating on innovative developments such as subcutaneous immunotherapy formulations to improve treatment convenience and enhance patient adherence. Subcutaneous immunotherapy formulations are injectable cancer treatments designed to deliver immune-modulating agents beneath the skin, offering efficacy comparable to intravenous administration while reducing treatment time and procedural complexity. For example, in December 2024, Bristol Myers Squibb received approval from the U.S. Food and Drug Administration for Opdivo Qvantig, a subcutaneous co-formulation of nivolumab and hyaluronidase. This formulation demonstrated non-inferior pharmacokinetics, comparable safety, and similar overall response rates to the intravenous version in the Phase 3 CheckMate-67T trial. The approval marked the introduction of the first subcutaneously administered PD-1 inhibitor, enabling faster administration and greater treatment flexibility for patients with solid tumors, including melanoma.

In October 2023, Bristol Myers Squibb acquired Mirati Therapeutics for approximately $4.8 billion. Through this acquisition, the company aims to strengthen and diversify its oncology portfolio by adding next-generation targeted therapies and expanding its presence in cancers driven by KRAS mutations. Mirati Therapeutics is a US-based developer of targeted oncology medicines and clinical-stage therapies focused on genetic and immunologic drivers of cancer.

Major companies operating in the melanoma therapeutics market are AstraZeneca plc, Eli Lilly and Company, Merck & Co. Inc., Novartis AG, Amgen Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Bristol-Myers Squibb Company, Oncolys BioPharma Inc., Iovance Biotherapeutics Inc., Eisai Co. Ltd., Seattle Genetics Inc., Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Nektar Therapeutics, Immutep Ltd., Partner Therapeutics Inc., Infinity Pharmaceuticals Inc., Spring Bank Pharmaceuticals Inc., AIM ImmunoTech Inc.

North America was the largest region in the melanoma therapeutics market in 2025. The regions covered in the melanoma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the melanoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the melanoma therapeutics market by increasing the cost of imported biologics, monoclonal antibodies, and small molecule inhibitors, which has affected the overall affordability of treatments. The impact is most pronounced in segments like monoclonal antibodies and targeted therapies, and in regions heavily reliant on imports such as North America and Europe. While tariffs create cost pressures, they also encourage local manufacturing and domestic production of therapies, potentially fostering innovation and reducing supply chain dependency over time.

The melanoma therapeutics market research report is one of a series of new reports that provides melanoma therapeutics market statistics, including melanoma therapeutics industry global market size, regional shares, competitors with a melanoma therapeutics market share, detailed melanoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the melanoma therapeutics industry. This melanoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Melanoma therapeutics refer to treatment approaches used for managing melanoma, a type of skin cancer that arises from melanocytes. These therapies act by targeting abnormal cells, either by destroying them directly or by inhibiting their growth and multiplication.

The main types of melanoma therapeutic drugs include monoclonal antibodies, small-molecule inhibitors, and others. Monoclonal antibodies are laboratory-produced therapeutic proteins that can bind to specific targets, such as antigens found on cancer cells. Treatment approaches include surgery, radiation therapy, immunotherapy, targeted therapy, and chemotherapy, and are administered through various routes including oral and injectable forms. The cancer types treated include superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, amelanotic melanoma, and others, which are diagnosed using methods such as dermatoscopy, sentinel lymph node biopsy, blood tests, X-ray, ultrasound, and CT scans.

The melanoma therapeutics market includes revenues earned by entities by providing stereotactic radiosurgery, stereotactic ablative radiation therapy, intralesional therapy, and palliative therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.